Related Experiment Video

Updated: May 15, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency

Hiromasa Takeda1, Nagio Takigawa, Kadoaki Ohashi

  • 1Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

Experimental Cell Research
|January 1, 2013
PubMed

Insights

Vandetanib shows effectiveness against EGFR-mutant non-small cell lung cancer (NSCLC) cells lacking PTEN. This study investigated vandetanib

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) with EGFR mutations is a significant challenge.
  • PTEN loss is implicated in resistance to targeted therapies.
  • Vandetanib targets RET, VEGFR, and EGFR signaling pathways.

Purpose of the Study:

  • To investigate the efficacy of vandetanib in EGFR-mutant NSCLC cells with PTEN loss.
  • To compare vandetanib with gefitinib in PTEN-altered NSCLC models.
  • To elucidate the role of PTEN status in response to EGFR inhibitors.

Main Methods:

  • Utilized two EGFR-mutant NSCLC cell lines: PC-9 (PTEN wild type) and NCI-H1650 (PTEN null).
  • Manipulated PTEN expression via gene transfection and shRNA-mediated knockdown.
  • Assessed drug effectiveness using in vitro assays and a xenograft mouse model.

Main Results:

  • NCI-H1650 (PTEN null) cells were more sensitive to vandetanib than gefitinib.
  • Vandetanib and gefitinib suppressed EGFR and MAPK activation in PTEN-null cells.
  • PTEN knockdown in PC-9 cells induced gefitinib resistance, while PTEN restoration in NCI-H1650 cells showed varied responses in vitro and in vivo.

Conclusions:

  • Vandetanib demonstrates potential efficacy in EGFR-mutant NSCLC with PTEN loss.
  • PTEN absence may contribute to vandetanib's activity in this context.
  • Further research is warranted to explore PTEN's role in vandetanib response in NSCLC.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...